The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Activation of -Glucocerebrosidase Reduces Pathological -Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons
Open accessAbstract
UNLABELLED: Parkinson's disease (PD) is characterized by the accumulation of α-synuclein (α-syn) within Lewy body inclusions in the nervous system. There are currently no disease-modifying therapies capable of reducing α-syn inclusions in PD. Recent data has indicated that loss-of-function mutations in the GBA1 gene that encodes lysosomal β-glucocerebrosidase (GCase) represent an important risk factor for PD, and can lead to α-syn accumulation. Here we use a small-molecule modulator of GCase to determine whether GCase activation within lysosomes can reduce α-syn levels and ameliorate downstream toxicity. Using induced pluripotent stem cell (iPSC)-derived human midbrain dopamine (DA) neurons from synucleinopathy patients with different PD-linked mutations, we find that a non-inhibitory small molecule modulator of GCase specifically enhanced activity within lysosomal compartments. This resulted in reduction of GCase substrates and clearance of pathological α-syn, regardless of the disease causing mutations. Importantly, the reduction of α-syn was sufficient to reverse downstream cellular pathologies induced by α-syn, including perturbations in hydrolase maturation and lysosomal dysfunction. These results indicate that enhancement of a single lysosomal hydrolase, GCase, can effectively reduce α-syn and provide therapeutic benefit in human midbrain neurons. This suggests that GCase activators may prove beneficial as treatments for PD and related synucleinopathies. SIGNIFICANCE STATEMENT: The presence of Lewy body inclusions comprised of fibrillar α-syn within affected regions of PD brain has been firmly documented, however no treatments exist that are capable of clearing Lewy bodies. Here, we used a mechanistic-based approach to examine the effect of GCase activation on α-syn clearance in human midbrain DA models that naturally accumulate α-syn through genetic mutations. Small molecule-mediated activation of GCase was effective at reducing α-syn inclusions in neurons, as well as associated downstream toxicity, demonstrating a therapeutic effect. Our work provides an example of how human iPSC-derived midbrain models could be used for testing potential treatments for neurodegenerative disorders, and identifies GCase as a critical therapeutic convergence point for a wide range of synucleinopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Self-citationImpaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024 · cited 1×
“Based on previous studies, we hypothesize that the reduction of GluCer makes -syn more amenable to degradation, through destabilization of -syn and subsequent clearance through the lysosomal system (Cuervo et al., 2004; Mazzulli et al., 2011).”
BackgroundKriks, S., Shim, J.-W., Piao, J., Ganat, Y. M., Wakeman, D. R., Xie, Z., Carrillo-Reid, L., Auyeung, G., Antonacci, C., Buch, A., et al. (2011) · Nature · doi:10.1038/nature10648 · Cited by 1,907
(1998) · Europe PMC (PubMed Central) · Cited by 1,594
α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models
Cooper, A. A., Gitler, A. D., Cashikar, A., Haynes, C. M., Hill, K. J., Bhullar, B., Liu, K., Xu, K., Strathearn, K. E., Liu, F., et al. (2006) · Science · doi:10.1126/science.1129462 · Cited by 1,376
Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
Self-citationSoldner, F., Laganière, J., Cheng, A. W., Hockemeyer, D., Gao, Q., Alagappan, R., Khurana, V., Golbe, L. I., Myers, R. H., Lindquist, S., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.019 · Cited by 728
Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains
Gegg, M. E., Burke, D., Heales, S. J. R., Cooper, J. M., Hardy, J., Wood, N. W., & Schapira, A. H. V. (2012) · Annals of Neurology · doi:10.1002/ana.23614 · Cited by 564
Schöndorf, D. C., Aureli, M., McAllister, F. E., Hindley, C. J., Mayer, F., Schmid, B., Sardi, S. P., Valsecchi, M., Hoffmann, S., Schwarz, L. K., et al. (2014) · Nature Communications · doi:10.1038/ncomms5028 · Cited by 543
Gitler, A. D., Chesi, A., Geddie, M. L., Strathearn, K. E., Hamamichi, S., Hill, K. J., Caldwell, K. A., Caldwell, G. A., Cooper, A. A., Rochet, J.-C., et al. (2009) · Nature Genetics · doi:10.1038/ng.300 · Cited by 535
Identification and Rescue of α-Synuclein Toxicity in Parkinson Patient–Derived Neurons
Chung, C. Y., Khurana, V., Auluck, P. K., Tardiff, D. F., Mazzulli, J. R., Soldner, F., Baru, V., Lou, Y., Freyzon, Y., Cho, S., et al. (2013) · Science · doi:10.1126/science.1245296 · Cited by 441
Self-citationRyan, S. D., Dolatabadi, N., Chan, S. F., Zhang, X., Akhtar, M. W., Parker, J., Soldner, F., Sunico, C. R., Nagar, S., Talantova, M., et al. (2013) · Cell · doi:10.1016/j.cell.2013.11.009 · Cited by 434
Neuropathology underlying clinical variability in patients with synucleinopathies
Halliday, G. M., Holton, J. L., Revesz, T., & Dickson, D. W. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0852-9 · Cited by 430
Glucocerebrosidase activity in Parkinson’s disease with and without GBA mutations
Alcalay, R. N., Levy, O. A., Waters, C. H., Fahn, S., Ford, B., Kuo, S.-H., Mazzoni, P., Pauciulo, M. W., Nichols, W. C., Gan-Or, Z., et al. (2015) · Brain · doi:10.1093/brain/awv179 · Cited by 392
Mazzulli, J. R., Zunke, F., Isacson, O., Studer, L., & Krainc, D. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520335113 · Cited by 386
Self-citationMcCann, H., Stevens, C. H., Cartwright, H., & Halliday, G. M. (2014) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(13)70017-8 · Cited by 364
Osellame, L. D., Rahim, A. A., Hargreaves, I. P., Gegg, M. E., Richard-Londt, A., Brandner, S., Waddington, S. N., Schapira, A. H. V., & Duchen, M. R. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.014 · Cited by 334
Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases
Duda, J. E., Giasson, B. I., Mabon, M. E., Lee, V. M. ‐., & Trojanowski, J. Q. (2002) · Annals of Neurology · doi:10.1002/ana.10279 · Cited by 329
Sardi, S. P., Clarke, J., Kinnecom, C., Tamsett, T. J., Li, L., Stanek, L. M., Passini, M. A., Grabowski, G. A., Schlossmacher, M. G., Sidman, R. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108197108 · Cited by 319
Cullen, V., Sardi, S. P., Ng, J., Xu, Y., Sun, Y., Tomlinson, J. J., Kolodziej, P., Kahn, I., Saftig, P., Woulfe, J., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22400 · Cited by 303
The Metabolism of Glucocerebrosides
Brady, R. O., Kanfer, J., & Shapiro, D. (1965) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)97611-8 · Cited by 278
Cerebrospinal fluid lysosomal enzymes and alpha‐synuclein in Parkinson's disease
Parnetti, L., Chiasserini, D., Persichetti, E., Eusebi, P., Varghese, S., Qureshi, M. M., Dardis, A., Deganuto, M., De Carlo, C., Castrioto, A., et al. (2014) · Movement Disorders · doi:10.1002/mds.25772 · Cited by 266
Sardi, S. P., Clarke, J., Viel, C., Chan, M., Tamsett, T. J., Treleaven, C. M., Bu, J., Sweet, L., Passini, M. A., Dodge, J. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220464110 · Cited by 251
The relationship between glucocerebrosidase mutations and Parkinson disease
Migdalska‐Richards, A., & Schapira, A. H. V. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13385 · Cited by 231
Thayanidhi, N., Helm, J. R., Nycz, D. C., Bentley, M., Liang, Y., & Hay, J. C. (2010) · Molecular Biology of the Cell · doi:10.1091/mbc.e09-09-0801 · Cited by 229
Progressive decline of glucocerebrosidase in aging and Parkinson's disease
Rocha, E. M., Smith, G. A., Park, E., Cao, H., Brown, E., Hallett, P., & Isacson, O. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.177 · Cited by 210
Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage
Cleeter, M. W. J., Chau, K.-Y., Gluck, C., Mehta, A., Hughes, D. A., Duchen, M., Wood, N. W., Hardy, J., Mark Cooper, J., & Schapira, A. H. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.10.010 · Cited by 201
Improved Immunodetection of Endogenous α-Synuclein
Lee, B. R., & Kamitani, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023939 · Cited by 177
Manning-Boğ, A. B., Schüle, B., & Langston, J. W. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.06.009 · Cited by 176
Rocha, E. M., Smith, G. A., Park, E. Y. H., Cao, H., Graham, A.-R., Brown, E., McLean, J. R., Hayes, M. A., Beagan, J. A., Izen, S. C., et al. (2015) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6307 · Cited by 162
Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons
Rocha, E. M., Smith, G. A., Park, E., Cao, H., Brown, E., Hayes, M. A., Beagan, J., McLean, J. R., Izen, S. C., Perez-Torres, E., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.09.009 · Cited by 160
Tsunemi, T., & Krainc, D. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt572 · Cited by 159
Self-citationMazzulli, J. R., Mishizen-Eberz, A. J., Giasson, B. I., Lynch, D. R., THOMAS, S. A., Nakashima, A., Nagatsu, T., Ota, A., & Ischiropoulos, H. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0896-06.2006 · Cited by 157
Self-citationGlucocerebrosidase is shaking up the synucleinopathies
Siebert, M., Sidransky, E., & Westbroek, W. (2014) · Brain · doi:10.1093/brain/awu002 · Cited by 155
Self-citationSchultheis, P. J., Fleming, S. M., Clippinger, A. K., Lewis, J. M., Tsunemi, T., Giasson, B. I., Dickson, D. W., Mazzulli, J. R., Bardgett, M. E., Haik, K. L., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt057 · Cited by 155
Self-citationPatnaik, S., Zheng, W., Choi, J. H., Motabar, O., Southall, N. T., Westbroek, W., Lea, W., Velayati, A., Goldin, E., Sidransky, E., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300063b · Cited by 139
Self-citationXu, Y. H., Sun, Y., Ran, H., Quinn, B., Witte, D. P., & Grabowski, G. A. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2010.12.014 · Cited by 139
van Weely, S., Brandsma, M., Strijland, A., Tager, J. M., & Aerts, J. M. F. G. (1993) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(93)90090-n · Cited by 137
Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs
Aflaki, E., Stubblefield, B. K., Maniwang, E., Lopez, G., Moaven, N., Goldin, E., Marugan, J., Patnaik, S., Dutra, A., Southall, N., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008659 · Cited by 126
Self-citationPark, J., Mehta, P. M., Cooper, A. A., Veivers, D., Heimbach, A., Stiller, B., Kubisch, C., Fung, V. S. C., Krainc, D., Mackay‐Sim, A., et al. (2011) · Human Mutation · doi:10.1002/humu.21527 · Cited by 122
Self-citationLoss of glucocerebrosidase 1 activity causes lysosomal dysfunction and α-synuclein aggregation
Bae, E.-J., Yang, N. Y., Lee, C.-S., Lee, H.-J., Kim, S., Sardi, S. P., & Lee, S. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.128 · Cited by 121
Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity
Yap, T. L., Velayati, A., Sidransky, E., & Lee, J. C. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.11.010 · Cited by 119
Self-citationCredle, J. J., Forcelli, P. A., Delannoy, M. R., Oaks, A. W., Permaul, E., Berry, D. L., Duka, V., Wills, J., & Sidhu, A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.02.005 · Cited by 113
Parkinson’s disease: From human genetics to clinical trials
van der Brug, M. P., Singleton, A., Gasser, T., & Lewis, P. A. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa8280 · Cited by 62
Sun, Y., Florer, J. B., Mayhew, C. N., Jia, Z., Zhao, Z., Xu, K., Ran, H., Liou, B., Zhang, W., Setchell, K. D. R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118771 · Cited by 57
Cited by
α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
Wong, Y. C., & Krainc, D. (2017) · Nature Medicine · doi:10.1038/nm.4269 · Cited by 897
Self-citationDopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease
Burbulla, L. F., Song, P., Mazzulli, J. R., Zampese, E., Wong, Y. C., Jeon, S., Santos, D. P., Blanz, J., Obermaier, C. D., Strojny, C., et al. (2017) · Science · doi:10.1126/science.aam9080 · Cited by 874
Self-citationExcessive burden of lysosomal storage disorder gene variants in Parkinson’s disease
Robak, L. A., Jansen, I. E., van Rooij, J., Uitterlinden, A. G., Kraaij, R., Jankovic, J., Heutink, P., Shulman, J. M., International Parkinson’s Disease Genomics Consortium (IPDGC), Nalls, M. A., et al. (2017) · Brain · doi:10.1093/brain/awx285 · Cited by 433
Self-citationMullin, S., Smith, L., Lee, K., D’Souza, G., Woodgate, P., Elflein, J., Hällqvist, J., Toffoli, M., Streeter, A., Hosking, J., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.4611 · Cited by 356
Role of dopamine in the pathophysiology of Parkinson’s disease
Zhou, Z. D., Yi, L. X., Wang, D. Q., Lim, T. M., & Tan, E. K. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00378-6 · Cited by 308
Metadata
- Authors
- Mazzulli, J. R., Zunke, F., Tsunemi, T., Toker, N. J., Jeon, S., Burbulla, L. F., Patnaik, S., Sidransky, E., Marugan, J. J., Sue, C. M., & Krainc, D.
- Venue
- Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2016-07-20
- Volume
- 36
- Issue
- 29
- Pages
- 7693-7706
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2495228129
- Cited by
- 273
- References
- 46
- FWCI
- 17.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.